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Abstract
Introduction Menopausal hormone therapy has been reported
to increase the risk of certain subtypes of breast cancer and to
be associated with a favorable survival. These associations
could either be due to an increased mammographic surveillance
or to a biological effect. We assessed these associations in a
Swedish cohort of postmenopausal breast cancer patients
holding information on mammographic examinations,
menopausal hormone therapy use, other breast cancer risk
factors, and cancer treatment.
Methods We analyzed 2,660 postmenopausal women aged 50
to 74 years, diagnosed with invasive breast cancer in 1993 to
1995 and followed until the end of 2003 (median follow-up, 9
years and 3 months). We assessed the influence of hormone
therapy before diagnosis on tumor characteristics and breast
cancer-specific survival. We analyzed hormone therapy before
diagnosis by regimen (estrogen–progestin therapy or estrogen
alone therapy), recency (current or past), and duration of use
(<5 years or ≥ 5 years).
Results Current use, but not past use, compared with never use
of hormone therapy before diagnosis seemed to be associated
with tumors of low grade and with improved breast cancer-
specific survival. The associations were stronger with longer
duration, but did not vary significantly by regimen. The favorable
survival among current users of hormone therapy was only partly
explained by differences in available tumor characteristics and
mammographic surveillance.
Conclusions We conclude that current menopausal hormone
therapy, especially long term, is associated with favorable tumor
characteristics and survival.
Introduction
Menopausal hormone therapy (MHT) increases the risk of
breast cancer. The risk increase is detectable after only a few
years of therapy, and disappears within 5 years after discontin-
uation [1]. Adding progestin to estrogen therapy seems to fur-
ther elevate the risk [1].
How MHT influences breast tumor characteristics is less well
studied, and the results are conflicting. The only randomized
controlled trial comparing estrogen–progestin therapy with
placebo therapy found women in the treated arm to have
slightly larger tumors with a higher proportion of lymph node
involvement compared with those in the untreated arm [2]. In
contrast, most observational studies either report no influence
of or a favorable effect of MHT on prognostic variables such
as tumor size, lymph node involvement, tumor grade, or recep-
tor status [3-14].
The recent sharp decline in MHT use has, especially in the
United States, been paralleled by a decline in the incidence of
estrogen receptor (ER)-positive tumors in women aged 50 to
69 years, supporting a link between MHT and tumors of cer-
tain characteristics [15]. Most, but not all, reports on MHT use
and breast cancer prognosis find a favorable survival among
users of MHT before diagnosis compared with nontreated
women [6,7,16-20]. It has been argued that these findings
CI: confidence interval; ER: estrogen receptor; MHT: menopausal hormone therapy; PR: progesterone receptor.Breast Cancer Research    Vol 10 No 5    Rosenberg et al.
Page 2 of 11
(page number not for citation purposes)
could be attributed to a higher mammographic surveillance in
MHT users, which might lead to earlier diagnosis and thereby
better tumor characteristics and survival [2].
To further elucidate the influence of MHT before diagnosis on
tumor characteristics and breast cancer survival, we have
studied 2,660 postmenopausal women with information on
mammographic examinations before diagnosis and other pos-
sible confounding factors.
Materials and methods
We used information from cases in a population-based
case–control study performed in Sweden from 1993 to 1995
[21]. Briefly, all women born in Sweden and aged 50 to 74
years at first diagnosis of invasive breast cancer in the Swed-
ish Cancer Register were eligible (n = 3,979), of whom 84%
(n = 3,345) participated by answering a mailed questionnaire.
The current study was approved by the seven medical ethical
review boards in Sweden. One of the ethical review boards
requested a renewed informed consent for this follow-up
study, while no such renewal was deemed necessary by the
other boards.
We retrieved information from the six Regional Cancer Regis-
ters on tumor characteristics, and found that 45% of nonpar-
ticipants compared with 32% of participants had lymph node
involvement and that nonparticipants had a 2 mm larger mean
tumor size compared with participants. The mean interval from
diagnosis to data collection was 4.3 months.
Data sources
Data on possible breast cancer risk factors, including detailed
information on the use of MHT, were collected through a
postal questionnaire [21]. We used the national registration
number, unique to each Swedish citizen, to retrieve the correct
patient records and register information. We collected infor-
mation on primary surgery, adjuvant treatment (endocrine ther-
apy, chemotherapy, and radiotherapy), and tumor
characteristics from surgical and oncological patient records
throughout Sweden. For 35 women we did not find any patient
records, and in those cases information on tumor characteris-
tics was collected from the six Regional Cancer Registers in
Sweden.
We visited 66 of the 68 units performing mammographies in
Sweden, and collected information on the date and reason for
the mammographies (screening or referral) performed within 5
years before diagnosis, excluding 3 months just before diag-
nosis to avoid registering diagnostic examinations. In the ques-
tionnaire, participants reported how many mammographies
they had undergone within 1 year and 5 years, respectively,
before diagnosis. This questionnaire information was used to
identify cases where we failed to retrieve information from
mammographic units.
We collected information on emigrations from the Swedish
National Population Registry, and the date and cause of death
until 31 December 2003 from the Swedish Causes of Death
Registry. The latter registry covers all residents in Sweden with
essentially no missing deaths, and has been shown to cor-
rectly classify 98% of breast cancer deaths [22]. The follow-
up is thus virtually complete.
Exclusions
Owing to recommendations from one ethical review board,
written informed consent was sought in that region before col-
lecting patient record data, and 67 women did not provide
informed consent. In addition, we excluded 152 women with
previous cancer (except nonmelanoma skin cancer), 75 cases
with noninvasive breast cancer, two cases with a cancer diag-
nosis other than breast cancer, and 24 cases diagnosed
before or after the inclusion period. Menopause was defined
as the age at last menstrual period or age at bilateral
oophorectomy, if it occurred 1 year or more prior to data col-
lection. Premenopausal women (n = 177) as well as women
below the age of 55 years with unknown age at menopause (n
= 188) were excluded. Thus, 2,660 cases were included in
the analyses.
Classifications
Recent mammography was defined as mammography within 2
years and 2 months before diagnosis (yes/no), in order to
cover the normal 2-year interval of mammographic screening
plus a 2-month delay. Grade was classified according to the
Nottingham histologic grade or the Bloom–Richardson scale
into three groups [23]. Tumors were considered ER-positive
or progesterone receptor (PR)-positive if they contained ≥
0.05 fmol receptor/μg DNA or ≥ 10 fmol receptor/mg protein.
MHT before diagnosis was categorized into four regimens:
use of estrogen (96% estradiol) in combination with progestin;
estrogen alone (71% estradiol, 25% conjugated estrogens,
4% other); oral estriol; or local estrogen. We further classified
MHT by duration of use (<5 years, ≥ 5 years) and by recency
of use (current if <6 months, and past if ≥ 6 months between
last use and diagnosis). Too few women reported use of pro-
gestin alone to be analyzed separately, and were therefore
excluded from the analyses (three current users and 53 past
users). Oral estriol and local estrogen were not associated
with either tumor characteristics or survival (data not shown)
and were therefore not defined as MHT in the analyses. Con-
sequently, women who had only used these compounds were
considered unexposed to MHT in the subsequent analyses.
Adjuvant chemotherapy and endocrine therapy (mainly
tamoxifen) was classified as yes or no.
Statistical analyses
Follow-up started at the day of diagnosis, defined as first cyto-
logical or histopathological report of cancer. The outcome wasAvailable online http://breast-cancer-research.com/content/10/5/R78
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death from breast cancer (codes 174.9 and 50.9 according to
the ninth and tenth revisions of international classification of
diseases, respectively). The end of follow-up was defined as
the date of death, the date of emigration, or 31 December
2003, whichever came first. During 21,938 person-years of
follow-up, one woman emigrated, 414 women died from
breast cancer, and 269 women died from other causes.
We calculated breast cancer mortality rates by background
and tumor characteristics as the number of breast cancer
deaths per 100 person-years. Chi-square tests were per-
formed to detect different distributions of tumor characteris-
tics in relation to MHT use. We used polytomous multiple
logistic regression to estimate odds ratios with 95% confi-
dence intervals (CIs) for the associations between duration of
current MHT and tumor characteristics. This was done in a
case-only approach – where, for each tumor characteristic,
one tumor group (for instance, tumor size ≤ 10 mm) was used
as the control group, and tumor sizes of 11 to 20 mm, 21 to
50 mm, and >50 mm were the outcome groups. MHT was the
exposure, and never use of MHT was the reference group. Age
at diagnosis and recent mammography were included as
covariates.
In addition, we repeated the logistic regressions restricted to
women with a recent mammography. We used the Kap-
lan–Meier method for assessing cause-specific survival distri-
butions in relation to use of MHT. We compared cause-
specific mortality between categories of MHT users in relation
to never users with the Cox proportional hazards model.
Potential confounders were recent mammography, socioeco-
nomic status, age at first birth, parity, body mass index (kg/m2),
height, recent alcohol intake, recent smoking, age at meno-
pause, age at menarche, benign breast disease, and family his-
tory. If the factor was associated with breast cancer mortality,
crude and stratified Cox models were compared. Tumor char-
acteristics and treatment are intermediates between MHT
exposure and breast cancer survival, and were thus included
in the Cox models to assess the extent to which they could
explain the observed associations. In addition, we restricted
the final Cox models to women with a recent mammography.
We tested the proportional hazards assumption of duration ≥
5 years of current MHT versus no MHT by dividing the follow-
up time into >5 years or <5 years after diagnosis.
We used the SAS Statistical Software, version 9.1 (SAS Insti-
tute Inc., Cary, NC, USA) for all analyses.
Results
The median follow-up time was 9 years and 3 months (range,
4 months to 10 years and 3 months). Breast cancer mortality
rates in relation to different background and tumor character-
istics are presented in Table 1. Mortality rates were slightly
higher in the highest and lowest age groups. Mortality rates
did not vary by socioeconomic status, but varied as expected
with the tumor characteristics. Women who had undergone a
recent mammography had a slightly lower mortality rate com-
pared with other women (Table 1).
No difference in the distribution of age or of tumor character-
istics was noted when comparing past use and never use of
MHT. Past users were more often of high socioeconomic sta-
tus and seemed to have been through a recent mammography
more often (Table 2). Current users of MHT were younger at
date of diagnosis, were more often of high socioeconomic sta-
tus, and more often had undergone a recent mammography.
Current use of MHT was not associated with tumor size or
lymph node involvement. On the other hand, low-grade
tumors, tumors of nonductal histological type, ER+PR+ tumors,
and ER-PR+ tumors were more often found among current
MHT users compared with never MHT users (Table 2).
We subdivided current MHT use by regimen and duration
(Table 3). Recent mammography and tumor characteristics
did not vary significantly by regimen among current users of
MHT. Long-term current use (≥ 5 years) compared with short-
term current use (<5 years) was associated with smaller tumor
size, but did not seem to differ in lymph node involvement.
Long-term current users more often had tumors of low grade,
of nonductal histological type, and of ER+PR+ status com-
pared with short-term current users (Table 3). There were
fewer patients with a recent mammography among long-term
current users compared with short-term current users, but the
difference was not significant (Table 3).
We performed polytomous logistic regression with one group
in each tumor characteristic as the control group and the other
groups as the case groups, comparing long-term and short-
term current use with never use and adjusting for age at diag-
nosis and recent mammography (Table 4). The odds ratios
were only marginally influenced by age at diagnosis and mam-
mography use, and the results were thus essentially the same
as those presented in Table 3. The odds ratio of being diag-
nosed with a grade 3 tumor instead of a grade 1 tumor was
0.3 (95% CI, 0.2 to 0.5) for long-term current use compared
with never users of MHT. As current use of MHT was related
to recent mammography, and the use of mammography is
related to breast cancer survival, we repeated the regression
analyses restricted to women with a recent mammography,
and the results were essentially unaltered apart from the esti-
mates among long-term current use compared with never use
regarding tumor size, where the point estimates for tumor sizes
21 to 50 mm and >50 mm were closer to unity, and their CIs
were nonsignificant (data not shown).
Figure 1 shows Kaplan–Meier plots for never use, past use,
and current use of MHT (Figure 1a) as well as by regimen (Fig-
ure 1b) and by duration (Figure 1c). Almost 20% of past users
and never users had died from breast cancer 10 years afterBreast Cancer Research    Vol 10 No 5    Rosenberg et al.
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Table 1
Background and tumor characteristics in relation to breast cancer mortality
Breast cancer deaths Persons Mortality ratea
Total 414 2,660 1.9
Age at diagnosis
50 to 54 years 61 345 2.1
55 to 59 years 84 578 1.7
60 to 64 years 89 570 1.9
65 to 69 years 96 661 1.8
70 to 74 years 84 506 2.1
Socioeconomic statusb
Low 209 1,335 1.9
High 201 1,308 1.9
Missing 4 17 3.0
Recent mammography
Yes 205 1,502 1.6
No 149 895 2.0
Missing 60 263 3.0
Tumor size
≤ 10 mm 33 728 0.5
11 to 20 mm 138 1,153 1.4
21 to 50 mm 196 689 3.8
>50 mm 38 70 9.8
Missing 9 20 7.6
Lymph node involvement
0 lymph nodes 128 1,750 0.8
1 to 3 lymph nodes 114 546 2.6
>3 lymph nodes 147 269 9.4
Missing 25 95 4.0
Grade
1 9 272 0.4
2 73 742 1.1
3 199 764 3.4
Missing 128 882 1.8
Histology
Ductal 301 1,901 1.9
Lobular 43 309 1.7
Other 60 415 1.7
Missing 10 35 4.3
Estrogen receptor (ER), progesterone receptor (PR) status
ER-PR- 100 336 4.2
ER+PR- 59 286 2.6
ER-PR+ 21 72 3.9
ER+PR+ 148 1172 1.5
Missing 86 794 1.3
aBreast cancer deaths per 100 person-years. bLow level includes blue-collar workers and low-level white-collar workers, whereas high level includes all other categories.Available online http://breast-cancer-research.com/content/10/5/R78
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Table 2
Distribution of background, tumor characteristics, and recent mammography in relation to use of menopausal hormone therapy
Never use Past use Current use Missing
Total 1,788 253 523 96
Age at diagnosis
50 to 54 years 154 (9) 23 (9) 148 (28) 20
55 to 59 years 320 (18) 45 (18) 181 (35) 32
60 to 64 years 381 (21) 54 (21) 116 (22) 19
65 to 69 years 521 (29) 70 (28) 55 (11) 15
70 to 74 years 412 (23) 61 (24) 23 (4) 10
P valuea 0.99 <0.0001
Socioeconomic statusb
Low 961 (54) 120 (47) 197 (38) 57
High 811 (46) 133 (53) 325 (62) 39
Missing 16 0 1 0
P valuea 0.042 <0.0001
Recent mammography
Yes 933 (59) 147 (64) 361 (73) 61
No 650 (41) 83 (36) 133 (27) 29
Missing 205 23 29 6
P valuea 0.15 <0.0001
Tumor size
≤ 10 mm 488 (28) 59 (24) 151 (29) 30
11 to 20 mm 759 (43) 115 (46) 240 (46) 39
21 to 50 mm 471 (27) 72 (29) 120 (23) 26
>50 mm 56 (3) 3 (1) 10 (2) 1
Missing 14 4 2 0
P valuea 0.17 0.15
Lymph node involvement
0 lymph nodes 1,164 (68) 164 (67) 353 (69) 69
1 to 3 lymph nodes 362 (21) 53 (22) 113 (22) 18
>3 lymph nodes 187 (11) 29 (12) 46 (9) 7
Missing 75 7 11 2
P valuea 0.90 0.44
Mean number of examined lymph nodes 10.4 10.8 10.7
Grade
1 164 (14) 17 (10) 78 (23) 13
2 524 (43) 65 (40) 133 (39) 20
3 520 (43) 81 (50) 130 (38) 33
Missing 580 90 182 30
P valuea 0.23 0.0002
Histology
Ductal 1,314 (74) 180 (72) 338 (66) 69
Lobular 186 (11) 31 (12) 81 (16) 11
Other 269 (15) 38 (15) 93 (18) 15Breast Cancer Research    Vol 10 No 5    Rosenberg et al.
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diagnosis, compared with approximately 10% of current users
(Figure 1a). Breast cancer survival did not differ by regimen of
current use (Figure 1b). When we compared short-term and
long-term current use, long-term users had a more favorable
breast cancer survival – particularly so during the first 3 years
after diagnosis (Figure 1c).
The hazard ratio for dying from breast cancer for current MHT
use compared with never MHT use was 0.57 (95% CI, 0.41 to
0.79; Table 5). The favorable survival among current MHT
users seemed to be present regardless of the receptor status:
hazard ratio in ER+PR+ tumors, 0.40 (95% CI, 0.22 to 0.72);
and hazard ratio in ER-PR-tumors, 0.56 (95% CI, 0.26 to 1.19)
(data not shown). Adjusting for other breast cancer risk factors
did not affect the survival estimate (data not shown). Restrict-
ing the analysis to women with a recent mammography did not
alter the estimate compared with adjusting for recent mam-
mography (data not shown). Past MHT use did not seem to
influence breast cancer survival (Table 5).
Long-term current users seemed to be the group with the most
favorable survival. The hazard ratio was 0.41 (95% CI, 0.25 to
0.67) for long-term current users and was 0.78 (95% CI, 0.51
to 1.19) for short-term current users compared with never
MHT use (Table 5). The regimen of use had no significant influ-
ence on the survival.
When we included tumor size and lymph node involvement in
the models, the estimates for various aspects of current MHT
use were slightly attenuated (Table 5). Owing to a large pro-
portion of missing information on grade and receptor status,
we were not able to include these characteristics simultane-
ously in the models. Adding either the ERPR status or grade
to models with tumor size and lymph node involvement did not
affect the survival estimates more than marginally (data not
shown).
The hazard ratio for the first 5 years after diagnosis was 0.48
(95% CI, 0.25 to 0.93), and was 0.71 (95% CI, 0.39 to 1.30)
for the period thereafter, when comparing current users with
never users and adjusting for age at diagnosis, recent mam-
mography, treatment, tumor size, and lymph node involvement.
The proportional hazards assumption was thus not signifi-
cantly rejected, but the favorable effect of MHT seemed to be
larger in the first 5 years after diagnosis than later during fol-
low-up. Excluding one woman with current use and 32 women
with never use of MHT who had distant metastases at diagno-
sis did not change the survival estimates (data not shown).
Discussion
Current use, but not past use, of MHT was associated with
tumor grade, histological type, and hormone receptor status,
but not associated with tumor size or lymph node status. The
breast cancer-specific survival was more favorable among cur-
rent users compared with never users of MHT after adjusting
for age and recent mammography. Available tumor character-
istics explained part of this observation. The protective effect
seemed to be more pronounced in the first 5 years after diag-
nosis. The association between current MHT use and tumor
characteristics and breast cancer-specific survival was more
pronounced among long-term users than short-term users, but
did not seem to vary according to the regimen of MHT.
Tumor progression from in situ tumor to metastatic tumor has,
according to the multistep view, been thought to be paralleled
by sequentially accumulating genetic alterations. According to
this view, tumors would progress from ER-positive to ER-neg-
ative and from low grade to high grade during tumor progres-
sion. An alternative hypothesis is that the tumor phenotype is
determined early during carcinogenesis and remains stable
during the clinical phase [24]. Gene expression studies have
found breast tumors clustering in a few groups related to ER
status and grade, rather than a continuum of patterns [24]. ER-
positive tumors versus ER-negative tumors, and low-grade
tumors versus high-grade tumors, also have mutually exclusive
Missing 19 4 11 1
P valuea 0.64 0.0004
Estrogen receptor (ER), progesterone receptor (PR) status
ER-PR- 227 (18) 37 (19) 55 (15) 17
ER+PR- 200 (16) 32 (17) 40 (11) 14
ER-PR+ 42 (3) 5 (3) 23 (6) 2
ER+PR+ 776 (62) 116 (61) 240 (67) 40
Missing 543 63 165 23
P valuea 0.91 0.0044
Data presented as n (%). Past use, last use at least 6 months before diagnosis; current use, last use <6 months before diagnosis. aTwo-sided global chi-squared P value for 
past use and current use, respectively, compared with no use of menopausal hormone therapy. bLow level includes blue-collar workers and low-level white-collar workers, 
whereas high level includes all other categories.
Table 2 (Continued)
Distribution of background, tumor characteristics, and recent mammography in relation to use of menopausal hormone therapyAvailable online http://breast-cancer-research.com/content/10/5/R78
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mutations – making transition to ER-negative tumors and to
high-grade tumors, respectively, during late tumor progression
less likely [25]. One study compared tumor characteristics in
tumors diagnosed at first screening and subsequent screen-
ing rounds, and found that tumor size and lymph node involve-
ment was more advanced in the first round, whereas tumor
grade did not differ between rounds [26]. In the light of these
findings, it seems plausible that receptor status and tumor
grade are relatively stable characteristics reflecting an estab-
lished phenotype, while tumor size and lymph node involve-
ment reflect a combination of the phenotype and age of the
tumor.
After taking mammographic surveillance before diagnosis
(mostly screening-based settings) into consideration, most
observational studies have found little association between
current MHT use and time-dependent tumor characteristics,
such as tumor size and lymph node involvement [3,7-9,11-
13,27,28]. Most previous studies have found an association
between MHT use and prognostic factors reflecting the biol-
ogy of the tumors – that is, low-grade tumors
[3,5,9,10,12,14,29] – although conflicting results exist [8,13].
In the Women's Health Initiative randomized clinical trials
[2,30], women treated with estrogen alone or treated with
estrogen–progestin had slightly larger tumors and a higher
prevalence of lymph node involvement than untreated women.
For tumor grade, receptor status, and histological type, the
only significant difference reported in the randomized trials
was that women treated with estrogen alone were more likely
Table 3
Distribution of tumor characteristics, and recent mammography among current users of menopausal hormone therapy by type and 
duration
Therapy Duration
Estrogen–progestin Estrogen alone P valuea <5 years ≥ 5 years P valuea
Total 422 92 238 284
Recent mammography
Yes 301 (75) 55 (66) 0.11 171 (76) 189 (70) 0.13
No 102 (25) 28 (34) 53 (24) 80 (30)
Tumor size
≤ 10 mm 125 (30) 23 (25) 61 (26) 90 (32)
11 to 20 mm 186 (44) 51 (56) 0.19 101 (43) 139 (49) 0.010
21 to 50 mm 102 (24) 15 (16) 70 (30) 49 (17)
>50 mm 8 (2) 2 (2) 5 (2) 5 (2)
Lymph node involvement
0 lymph nodes 289 (70) 60 (67) 162 (69) 191 (69)
1 to 3 lymph nodes 86 (21) 24 (27) 0.38 47 (20) 65 (23) 0.36
>3 lymph nodes 39 (9) 6 (7) 25 (11) 21 (8)
Grade
1 69 (25) 10 (15) 21 (13) 57 (31)
2 99 (37) 32 (48) 0.11 57 (36) 76 (42) <0.0001
3 103(38) 24 (36) 80 (51) 50 (27)
Histology
Ductal 272 (66) 61 (68) 17 (74) 166 (60)
Lobular 69 (17) 10 (11) 0.37 34 (15) 46 (17) 0.0007
Other 73 (18) 19 (21) 27 (12) 66 (24)
Estrogen receptor (ER), progesterone receptor (PR) status
ER-PR- 45 (15) 9 (16) 34 (20) 21 (11)
ER+PR- 35 (12) 5 (9) 0.93 25 (15) 15 (8) 0.0062
ER-PR+ 19 (6) 4 (7) 13 (8) 10 (5)
ER+PR+ 196 (66) 39 (68) 99 (58) 140 (75)
Data presented as n (%). aGlobal chi-squared P value for type and duration, respectively.Breast Cancer Research    Vol 10 No 5    Rosenberg et al.
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to have lobular tumors than ductal tumors. The discrepancy
between these results and those from observational studies is
puzzling. It could be that observational studies finding similar
or smaller tumors among MHT users have not fully corrected
for lead-time bias, while the absence of association between
MHT use and low-grade tumors in the randomized trials might
be due to low numbers, the 40% noncompliance, and possibly
the high proportion of obese women.
Seven studies [6,7,16,18-20,31] out of the eight previous
studies [6,7,16-20,31] support our finding of a favorable sur-
vival after breast cancer among MHT users compared with
nonusers. Two screening-based studies found reduced breast
cancer-specific mortality after adjustment for tumor size and
lymph node involvement [7,20], and one of them also for tumor
grade. Two studies examined duration of use, but, in contrast
to our findings, they found no association [19,20]. The only
other study to examine the regimen of MHT found a nonsignif-
icantly lower mortality with estrogen–progestin use compared
with estrogen alone [16]. All studies that have evaluated
recency of use, including ours, have found the improved sur-
vival to be mainly confined to current use [7,16,18].
The favorable breast cancer survival among current MHT
users was more pronounced in the first 5 years after diagnosis
than thereafter. This is in line with the finding that more aggres-
sive breast cancer cases have a peak mortality after around 2
years, while less aggressive breast cancer cases have a low
but constant mortality for >10 years after diagnosis [32]. If our
follow-up had lasted longer, therefore, the expected survival
benefit due to MHT would have diminished.
As MHT increases the risk of breast cancer after only a few
years, and this risk disappears shortly after ceasing, MHT
probably acts as a late-stage promoter of breast cancer. The
epidemiological findings of an association between current
MHT use and low-grade, receptor-positive tumors indicate
that MHT may promote preclinical tumors with less malignant
Table 4
Duration of current use relative to never use of menopausal hormone therapy and risk of breast tumor characteristics
<5 years current MHT ≥ 5 years current MHT
Crude Adjusteda Crude Adjusteda
Tumor size
≤ 10 mm Reference Reference Reference Reference
11 to 20 mm 1.1 (0.8 to 1.6) 1.1 (0.8 to 1.7) 1.0 (0.7 to 1.3) 1.0 (0.8 to 1.4)
21 to 50 mm 1.4 (0.9 to 2.0) 1.2 (0.8 to 1.9) 0.6 (0.4 to 0.9) 0.6 (0.4 to 0.9)
>50 mm 1.0 (0.4 to 2.6) 0.8 (0.3 to 2.3) 0.6 (0.2 to 1.6) 0.7 (0.2 to 1.7)
Lymph node involvement
0 lymph nodes Reference Reference Reference Reference
1 to 3 lymph nodes 1.0 (0.7 to 1.4) 0.8 (0.5 to 1.2) 1.2 (0.9 to 1.7) 1.1 (0.8 to 1.6)
>3 lymph nodes 0.9 (0.6 to 1.5) 0.8 (0.5 to 1.4) 0.7 (0.4 to 1.1) 0.6 (0.4 to 1.1)
Grade
1 Reference Reference Reference Reference
2 0.9 (0.5 to 1.6) 1.3 (0.7 to 2.4) 0.4 (0.3 to 0.7) 0.5 (0.3 to 0.7)
3 1.3 (0.8 to 2.3) 1.5 (0.8 to 2.7) 0.3 (0.2 to 0.5) 0.3 (0.2 to 0.5)
Histology
Ductal Reference Reference Reference Reference
Lobular 1.4 (1.0 to 2.2) 1.5 (1.0 to 2.5) 1.9 (1.3 to 2.8) 2.0 (1.4 to 2.9)
Other 0.8 (0.5 to 1.2) 0.9 (0.5 to 1.4) 2.0 (1.4 to 2.7) 2.0 (1.4 to 2.8)
Estrogen receptor (ER), progesterone receptor (PR) status
ER-PR- Reference Reference Reference Reference
ER+PR- 0.9 (0.5 to 1.5) 1.2 (0.6 to 2.4) 0.9 (0.4 to 1.8) 1.0 (0.5 to 2.1)
ER-PR+ 1.9 (0.9 to 4.0) 1.5 (0.6 to 3.7) 2.6 (1.1 to 6.0) 2.8 (1.2 to 6.7)
ER+PR+ 0.9 (0.6 to 1.4) 1.1 (0.7 to 1.8) 2.0 (1.2 to 3.3) 2.1 (1.3 to 3.6)
Data presented as the odds ratio (95% confidence interval) relative to never users of menopausal hormone therapy (MHT). For each tumor characteristic, the first row is the 
control group, and the other groups are the case groups. Never use of MHT is the reference group, and <5 years or > 5 years of current MHT are the exposure groups. 
aAdjusted for recent mammography (yes/no) and age at diagnosis (5-year categories).Available online http://breast-cancer-research.com/content/10/5/R78
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tumor characteristics. Consequently, we think that current
MHT use affects survival through biological effects on the
tumor. We cannot, however, rule out an influence of a healthy
women effect, or of lead-time bias. The highest risks of getting
breast cancer are found among long-term users, current users,
or estrogen–progestin users [1]. If MHT influences the tumor
phenotype, these subgroups are likely to be most affected,
and our findings of favorable tumor characteristics and
improved survival in these women are plausible.
The use of MHT has dropped since 2002 in the United States
[33,34], and since 1999 in Sweden [35]. A decreased inci-
dence of ER-positive breast cancer in women aged 50 to 69
years has been reported after 2002 [33,34], and a common
belief is that this decrease is due to the decreased use of
MHT. As we and other workers have found MHT linked to
tumors of low aggressiveness, we think a possible decreased
breast cancer incidence due to decreased use of MHT will be
accompanied by a much smaller decrease in breast cancer
mortality, which will probably not be possible to detect at the
population level.
The strengths of the present study are the population-based
setting with a high participation rate, the detailed information
on MHT use and other breast cancer risk factors, information
on tumor characteristics as well as surgical and adjuvant treat-
ment, only one patient being lost to follow-up, and high-quality
information on the cause of death [22].
There are limitations to the present study. Among the eligible
cancer cases in the study, 16% did not participate. Nonpartic-
ipants had somewhat larger tumors and a higher proportion of
lymph node involvement. If nonparticipants using MHT had
worse tumor characteristics than participants using MHT, or if
nonparticipants not using MHT had better tumor characteris-
tics than participants not using MHT, our results would be
biased – but this seems unlikely. Receptor status was
assessed at seven different laboratories, and many different
pathologists classified the tumor size, lymph node involve-
ment, tumor grade, and histological type. The proportion of
missing values was high for some of these variables. The mis-
classification due to the decentralized analyses as well as the
distribution of missing values was probably not related to MHT
use, and should thus be nondifferential. We lack information
on MHT use after diagnosis. Women diagnosed with breast
cancer were strongly recommended not to use MHT – so even
if some women used MHT after diagnosis, this was rarely
reported in the surgical and oncological patient records. We
do not, however, believe that MHT after diagnosis could influ-
ence our results more than marginally, being a probably rare
exposure with an unknown and probably small effect on sur-
vival [36]. Even though our study included more than 2,500
women diagnosed with breast cancer, the power for many of
the subgroup analyses was small and precluded firm
conclusions.
Figure 1
Kaplan–Meier plots of breast cancer-specific survival in relation to use  of menopausal hormone therapy Kaplan–Meier plots of breast cancer-specific survival in relation to 
use of menopausal hormone therapy. (a) No use, current use, or 
past use. (b) No use or current use by regimen. (c) No use or current 
use by duration.Breast Cancer Research    Vol 10 No 5    Rosenberg et al.
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Conclusion
We found that use of MHT at the time of breast cancer diag-
nosis was associated with lower tumor grade, lobular or other
nonductal histology, positive receptor status, and with a favo-
rable breast cancer survival. Mammographic surveillance did
not explain our results. As the tumor grade and receptor status
seem to be relatively stable characteristics that are not sensi-
tive to lead-time bias, we believe that MHT induces tumors of
certain phenotypes.
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